囊性纤维化中的持续葡萄糖监测与糖化血红蛋白:临床相关性及对囊性纤维化相关糖尿病诊断的意义
这项前瞻性观察研究纳入77例成人囊性纤维化患者,在间隔3个月的2至3个时间点测量持续葡萄糖监测(CGM)和糖化血红蛋白(HbA1c)。CGM高血糖和血糖变异性指标与营养状态和肺功能相关;HbA1c与平均葡萄糖(AG)相关(R2=0.71,P<0.001);AG及多项CGM指标区分囊性纤维化相关糖尿病(CFRD)的曲线下面积和正确分类率高于HbA1c。
要点
- 77例成人囊性纤维化患者中31例符合美国糖尿病协会推荐的CFRD诊断标准。
- HbA1c与CGM衍生平均葡萄糖相关(R2=0.71,P<0.001),回归关系与其他糖尿病群体相似。
- 时间>140 mg/dL占比17.5%和时间>180 mg/dL占比3.4%的切点识别CFRD灵敏度分别为87%和90%,特异度均为95%。
核心结论
- CGM的高血糖和血糖变异性指标在区分有无CFRD方面优于HbA1c。
- CGM衍生的平均葡萄糖在成人囊性纤维化中与HbA1c强相关,关系与其他糖尿病群体相似。
- 未来需要研究将CGM作为CFRD的诊断和筛查工具。
研究设计与样本
- 前瞻性观察研究,纳入77例成人囊性纤维化患者,在间隔3个月的2至3个时间点测量CGM和HbA1c。
主要发现
- 77例参与者中31例通过口服葡萄糖耐量试验和/或HbA1c符合美国糖尿病协会推荐的CFRD诊断标准。
- 在所有参与者中,CGM的高血糖和血糖变异性指标与营养状态和肺功能相关。
- HbA1c与平均葡萄糖相关(R2=0.71,P<0.001),该回归线与既往在1型糖尿病、2型糖尿病和健康志愿者中建立的回归线无显著差异。
- 时间>140 mg/dL占比17.5%的切点识别CFRD灵敏度为87%,特异度为95%;时间>180 mg/dL占比3.4%的切点灵敏度为90%,特异度为95%。
- 平均葡萄糖、标准差、时间>140 mg/dL占比、时间>180 mg/dL占比和时间>250 mg/dL占比的曲线下面积及CFRD正确分类参与者百分比均高于HbA1c。
关键数值与推荐
- CFRD诊断采用美国糖尿病协会推荐的诊断标准,通过口服葡萄糖耐量试验和/或HbA1c判定。
- 时间>140 mg/dL占比17.5%切点:识别CFRD灵敏度87%,特异度95%。
- 时间>180 mg/dL占比3.4%切点:识别CFRD灵敏度90%,特异度95%。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文结论指出未来需要研究将CGM作为CFRD的诊断和筛查工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The clinical utility and implications of continuous glucose monitoring (CGM) in cystic fibrosis (CF) are unclear. OBJECTIVE: We examined the correlation between CGM measures and clinical outcomes in adults with CF, investigated the relationship between hemoglobin A1c (HbA1c) and CGM-derived average glucose (AG), and explored CGM measures that distinguish cystic fibrosis-related diabetes (CFRD) from normal and abnormal glucose tolerance. METHODS: This prospective observational study included 77 adults with CF who had CGM and HbA1c measured at 2 to 3 time points 3 months apart. RESULTS: Thirty-one of the 77 participants met American Diabetes Association-recommended diagnostic criteria for CFRD by oral glucose tolerance testing and/or HbA1c. In all participants, CGM measures of hyperglycemia and glycemic variability correlated with nutritional status and pulmonary function. HbA1c was correlated with AG (R2 = 0.71, P < 0.001), with no significant difference between this regression line and that previously established in type 1 and type 2 diabetes and healthy volunteers. Cutoffs of 17.5% time > 140 mg/dL and 3.4% time > 180 mg/dL had sensitivities of 87% and 90%, respectively, and specificities of 95%, for identifying CFRD. Area under the curve and percent of participants correctly classified with CFRD were higher for AG, SD, % time > 140, > 180, and > 250 mg/dL than for HbA1c. CONCLUSION: CGM measures of hyperglycemia and glycemic variability are superior to HbA1c in distinguishing those with and without CFRD. CGM-derived AG is strongly correlated with HbA1c in adults with CF, with a similar relationship to other diabetes populations. Future studies are needed to investigate CGM as a diagnostic and screening tool for CFRD.
引用
- Scully KJ, Sherwood JS, Martin K, et al. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis. J Clin Endocrinol Metab. 2022. PMID: 34850006. doi:10.1210/clinem/dgab857
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。